Gossamer Bio Sets October 27 Vote on Up to 20.1M Share Issuance for $250M Private Placement
GOSS sits 20% above its 52-week low of $9.104.
Summary
Gossamer Bio's definitive proxy sets an October 27 vote on issuing up to 20.1 million shares tied to its $250 million private placement, with support agreements covering 23% of shares outstanding.
Key Events · Financing and Capital Events · GOSS
-
Special Meeting Set for October 27
Shareholders will vote on Proposal 1 (Nasdaq 5635(c)/(d) issuance approval) and Proposal 2 (adjournment authority) at a virtual meeting on October 27, 2026, with a record date of September 14, 2026.
-
Up to 20.1M Shares at Stake
Full exercise of the Initial Closing Pre-Funded Warrants (~2.23M shares), Second Closing Pre-Funded Warrants (~11.17M shares), and FDA Approval Warrants (~6.68M shares) would issue approximately 20,086,929 shares of Common Stock — more than 3x the 6,116,391 shares currently outstanding.
-
Support Agreements Cover 23% of Shares
Existing stockholders holding approximately 23% of outstanding Common Stock as of August 20, 2026, have agreed to vote in favor of the issuance, materially increasing the likelihood of approval.
-
New Director Also a Purchaser
Gregory A. Ciongoli, appointed to the Board on September 16, 2026, purchased Initial Closing Pre-Funded Warrants exercisable for ~22,337 shares and has agreed to purchase additional warrants at the Second Closing and upon FDA approval.
Analysis · GOSS · Life Sciences
The shareholder vote on Gossamer Bio's $250 million structured private placement is now set for October 27, 2026. The proxy statement confirms post-reverse-split figures: 6,116,391 shares outstanding as of the record date, and the potential issuance of approximately 20.1 million shares upon full exercise of the pre-funded warrants and FDA approval warrants — a highly dilutive event for existing holders. It was also disclosed that Gregory A. Ciongoli, newly appointed to the board on September 16, is a purchaser in the placement, and that support agreements cover roughly 23% of outstanding shares, improving the odds of approval. If shareholders reject the proposal, the company must resubmit every 90 days and the second closing commitments terminate if not completed by December 31, 2026.
How filings like this one have moved
In the 30 days to Oct 14, 2026, 28.9% of the 1472 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GOSS was trading at $10.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $67M. The 52-week trading range was $9.10 to $309.60. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.